The Early Coagulopathy for the Prognosis in Sepsis

Sponsor
Wuhan Union Hospital, China (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04582188
Collaborator
(none)
200
25.8

Study Details

Study Description

Brief Summary

In this cohort study, the parameters (TM, TAT, PIC, tPAIC, et al.) associated with the hemostatic system will be collected in sepsis patients when admitted to the Intensive Critical Unit. Parameters will be evaluated for their prognostic function of 28 days mortality.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The object of this study is to find the early mortality prognostic biomarkers within the hemostatic system in sepsis patients. Blood samples will be collected from sepsis patients at admission. Parameters reflect endothelial injury, such as thrombomodulin (TM), tissue type plasminogen activator inhibitor complex (tPAIC), parameters reflect procoagulation condition, such as thrombin-antithrombin complex (TAT), and parameters reflect hyperfibrinolysis, such as plasmin-plasmin inhibitor complex (PIC) will be tested. Based on the results of these parameters, sepsis patients will be divided into coagulation parameter normal or abnormal groups. Twenty-eight days of mortality will be determined by patient follow-up. Regression analysis will be used to evaluate the relationship between these parameters and the mortality of sepsis patients.

    Study Design

    Study Type:
    Observational [Patient Registry]
    Anticipated Enrollment :
    200 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    An Observational Study on the Prognostic Function of Early Coagulopathy in Sepsis Patients
    Anticipated Study Start Date :
    Nov 5, 2020
    Anticipated Primary Completion Date :
    Mar 31, 2021
    Anticipated Study Completion Date :
    Dec 31, 2022

    Outcome Measures

    Primary Outcome Measures

    1. 28-day all course mortality [28 days from ICU-admission]

    Secondary Outcome Measures

    1. Length of stay [28 days from ICU-admission]

    2. Length of using vasopressor [28 days from ICU-admission]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients admitted to ICU of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology from August 2020 to July 2022.

    • Patients diagnosed with sepsis. The criteria for diagnosis is: 1. Infection or suspected infection; 2. SOFA score ≥ 2.

    • Age interval: 18 years -- 80 years.

    • Gender: unlimited.

    • Signed informed consent form received.

    • Results of the coagulation parameters tested within 24 hours after admission are available.

    Exclusion Criteria:
    • Pregnant and lactating women.

    • With primary diseases that can cause thrombocytopenia or prolong prothrombin time, such as leukemia.

    • Patients with severe liver dysfunction.

    • Patients with anticoagulation or fibrinolysis medications within 72 hours before admission.

    • Patients are in a procoagulation condition, such as VTE patients, protein C or protein S deficient individuals.

    • Patients with chronic renal failure.

    • Patients need ECMO therapy.

    • Patients with severe cardiopulmonary diseases or nervous system diseases.

    • Patients at the end-stage of disease.

    • Patients without signed informed consent forms.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Wuhan Union Hospital, China

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Hua-Qing Shu, Associated Professor, Wuhan Union Hospital, China
    ClinicalTrials.gov Identifier:
    NCT04582188
    Other Study ID Numbers:
    • UHICU20201001
    First Posted:
    Oct 9, 2020
    Last Update Posted:
    Nov 6, 2020
    Last Verified:
    Nov 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Hua-Qing Shu, Associated Professor, Wuhan Union Hospital, China
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 6, 2020